Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tissue Transplantation01:24

Tissue Transplantation

1.1K
Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
1.1K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

1.7K
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
1.7K
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

84.7K
Overview
84.7K
Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

552
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
552

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Classical HLA allele and haplotype frequency estimates in US populations.

Human immunology·2026
Same author

Reductive carboxylation via isocitrate dehydrogenase 1 supports cardiac metabolic adaptation during oncometabolic stress.

bioRxiv : the preprint server for biology·2026
Same author

How Soon Is Now?: A Call for Inaction on Donor Left Ventricular Hypertrophy.

JACC. Heart failure·2026
Same author

Sex-based survival disparities persist in liver transplantation: MELD 3.0 fails to improve survival for waitlisted women.

Frontiers in transplantation·2026
Same author

The Phenotype List String Grammar for Enhanced Protein and Antigen Reporting in the Immunogenetic Context.

HLA·2026
Same author

Donor-Derived Cell-Free DNA as a Prognostic Biomarker After Heart Transplantation: The DEFINE-HT Study.

JACC. Heart failure·2026

Related Experiment Video

Updated: Feb 24, 2026

Personalized Peptide Arrays for Detection of HLA Alloantibodies in Organ Transplantation
08:07

Personalized Peptide Arrays for Detection of HLA Alloantibodies in Organ Transplantation

Published on: September 6, 2017

10.7K

HLA Population Genetics in Solid Organ Transplantation.

Evan P Kransdorf1, Marcelo J Pando, Loren Gragert

  • 11 Cedars-Sinai Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA. 2 Division of Laboratory Medicine and Pathology, Mayo Clinic Arizona, Phoenix, AZ. 3 Department of Pathology and Laboratory Medicine, Tulane University School of Medicine, New Orleans, LA. 4 Division of Nephrology and Hypertension, Mayo Clinic Arizona, Phoenix, AZ.

Transplantation
|August 24, 2017
PubMed
Summary

Human Leukocyte Antigen (HLA) population genetics informs the calculated panel-reactive antibody (CPRA) score. This metric is crucial for assessing transplant eligibility in sensitized patients and optimizing organ allocation.

More Related Videos

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

15.0K
Orthotopic Hind Limb Transplantation in the Mouse
07:15

Orthotopic Hind Limb Transplantation in the Mouse

Published on: February 12, 2016

12.4K

Related Experiment Videos

Last Updated: Feb 24, 2026

Personalized Peptide Arrays for Detection of HLA Alloantibodies in Organ Transplantation
08:07

Personalized Peptide Arrays for Detection of HLA Alloantibodies in Organ Transplantation

Published on: September 6, 2017

10.7K
In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

15.0K
Orthotopic Hind Limb Transplantation in the Mouse
07:15

Orthotopic Hind Limb Transplantation in the Mouse

Published on: February 12, 2016

12.4K

Area of Science:

  • Immunogenetics
  • Transplantation immunology
  • Population genetics

Background:

  • Human Leukocyte Antigen (HLA) genes are highly polymorphic, crucial for adaptive immunity and transplantation.
  • HLA compatibility is vital for successful solid organ transplantation outcomes.
  • Sensitized transplant candidates face challenges due to pre-formed antibodies against HLA antigens.

Purpose of the Study:

  • To review the principles of HLA population genetics.
  • To explain the mathematical basis of the calculated panel-reactive antibody (CPRA) score.
  • To underscore the importance of understanding CPRA for improving care for sensitized patients.

Main Methods:

  • Review of HLA population genetics principles.
  • Detailed explanation of the mathematical framework for CPRA calculation.
  • Analysis of CPRA's role in transplant candidate assessment.

Main Results:

  • HLA population genetics provides the foundation for the CPRA metric.
  • CPRA accurately predicts the likelihood of a positive crossmatch based on unacceptable HLA antigens.
  • CPRA is essential for determining access to transplantation for sensitized individuals.

Conclusions:

  • Understanding HLA population genetics and CPRA is fundamental for transplant clinicians.
  • CPRA is a critical tool for managing sensitized patients and organ allocation.
  • Continued innovation in sensitized patient care relies on these foundational principles.